Agendia, Inc.: Data Presented at the Miami Breast Cancer Conference Show MammaPrint and BluePrint Accurately Predict Pathologic Complete Response Rate Regardless of Age
(1) Results support use of Agendia's genomic tests to better tailor pre-operative treatment and timing for surgery Agendia, Inc., a world leader in precision oncology for breast cancer, announced new data from the prospective Neoadjuvant Breast Symphony Trial (NBRST) which demonstrate the predictive and prognostic abilities of MammaPrint and BluePrint , and underpin both assays' pre-operative utility in pre-and post-menopausal patients. A poster highlighting these findings will be presented at the 38 th Annual Miami Breast Cancer Conference. The poster, entitled Pathologic Complete Response...
Source: finanznachrichten.de